Aptahem (APTA) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was 617 KSEK, down from 1,058 KSEK year-over-year.

• Net loss after financial items improved to -2,008 KSEK from -2,729 KSEK year-over-year.

• Cash and cash equivalents at March 31, 2025, were 1,299 KSEK, compared to 3,499 KSEK a year earlier.

• Solid equity ratio of 96.03% at quarter-end.

• Strategic progress includes finalized clinical synopsis for Apta-1 phase 2 trial and intensified partnership discussions.

Financial highlights

• Operating income for Q1 2025 was 617 KSEK, with no reported net sales.

• Operating expenses totaled -2,625 KSEK, mainly from external and personnel costs.

• Net result per share was -0.17 SEK, compared to -0.006 SEK year-over-year.

• Cash flow from operations was -2,157 KSEK; cash decreased by 2,834 KSEK during the quarter.

• Accumulated capitalized development costs reached 61,521 KSEK.

Outlook and guidance

• Focus remains on advancing Apta-1 into phase 2 clinical trials targeting acute urogenital, renal, and pulmonary conditions.

• Ongoing and deepening partnership discussions with international biotech and pharma companies.

• New share issue of approximately 9.7 MSEK to fund continued business development and potential partnerships.